ESTABLISHMENT OF AN ANIMAL-MODEL FOR PULMONARY FIBROSIS IN MICE USING MONOCROTALINE

被引：17

作者：

HAYASHI, S ^{[1
]}

MITSUMORI, K ^{[1
]}

IMAIDA, K ^{[1
]}

IMAZAWA, T ^{[1
]}

YASUHARA, K ^{[1
]}

UNEYAMA, C ^{[1
]}

HAYASHI, Y ^{[1
]}

机构：

[1] NATL INST HYG SCI,DIV PATHOL,SETAGAYA KU,TOKYO 158,JAPAN

来源：

TOXICOLOGIC PATHOLOGY | 1995年 / 23卷 / 01期

关键词：

PYRROLIZIDINE ALKALOID; CHEMICAL-INDUCED; DIFFUSE ALVEOLAR DAMAGE; INTERSTITIAL PNEUMONIA; HISTOPATHOLOGY; ELECTRON MICROSCOPY; ICR MICE;

D O I：

10.1177/019262339502300108

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

A preliminary attempt at experimental induction of pulmonary fibrosis in which male ICR mice received 15 weekly sc injections of 200 or 100 mg/kg monocrotaline (MC) revealed that most animals treated with the larger dose died of severe interstitial pneumonia, whereas those given 100 mg/kg exhibited only relatively slight lung injury. Based on these results, male mice were administered sc injections of 200 and 100 mg/kg MC once a week for 9 and 18 times, respectively, and then maintained without any further treatment until week 28 after the start. Mice treated with 200 mg/kg MC showed severe pulmonary damage and died by week 25. Mortalities also occurred in the 100-mg group from week 16, with 11 of 40 animals surviving at the termination of the experiment. Histologically, both dose groups demonstrated severe interstitial pneumonia and/or pulmonary fibrosis. Ultrastructurally, inflammatory edema possibly attributable to injuries of alveolar capillary endothelial cells was observed in the high-dose group at week 8, and there was a remarkable increase in collagen fibers in alveolar septa in this group thereafter. The present study results suggest that lung injuries induced by MC treatment progress to irreversible lung fibrosis and that this animal model may have advantage for studying the pathogenesis of lung cancers in patients with pulmonary fibrosis.

引用

页码：63 / 71

页数：9

共 29 条

[1]

Adamson I.Y.R., Bowden D.H., The pathogenesis of bleomycin-induced pulmonary fibrosis in mice, Am. J. Pathol., 77, pp. 185-198, (1974)

[2]

Crystal R.G., Bitterman P.B., Rennard S.I., Hance A.J., Koegh B.A., Interstitial lung disease of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract, N. Eng. J. Med., 310, pp. 154-166, (1984)

[3]

Crystal R.G., Fulmer J.D., Roberts W.C., Moss M.L., Line B.R., Reynolds H.V., Idiopathic pulmonary fibrosis. Clinical histologic, radiographic, physiologic, scintigraphic, cyotologic, and biochemical aspects, Ann. Intern. Med., 85, pp. 769-788, (1976)

[4]

Czer G.T., Marsh J., Konopka R., Moser K.M., Low-dose PGI2 prevents monocrotaline-induced thromboxane production and lung injury, J. Appl. Physiol., 60, pp. 464-471, (1986)

[5]

Doherty D.E., Hirose N., Zagarella L., Cherniack R.M., Prolonged monocyte accumulation in the lung during bleomycin-induced pulmonary fibrosis: A noninvasive assessment of monocyte kinetics by scintigraphy, Lab. Invest., 66, pp. 231-242, (1992)

[6]

Fraire A.E., Greenberg S.D., Carcinoma and diffuse interstitial fibrosis of lung, Cancer, 31, pp. 1078-1086, (1973)

[7]

Fulmer J.D., Crystal R.G., RG C., The biochemical basis of pulmonary function

[8]

Ghodsi F., Will J.A., Changes in pulmonary structure and function induced by monocrotaline intoxication, Am. J. Physiol., 240, pp. 149-155, (1981)

[9]

Hance A.J., Crystal R.G., The connective tissue of lung, Am. Rev. Resp. Dis., 112, pp. 657-711, (1975)

[10]

Hicks R., Pulmonary fibrosis: Allergies, dust diseases and drugs, 12, pp. 304-309, (1984)

← 1 2 3 →